1. Home
  2. AERT vs RNTX Comparison

AERT vs RNTX Comparison

Compare AERT & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aeries Technology Inc.

AERT

Aeries Technology Inc.

HOLD

Current Price

$0.30

Market Cap

29.3M

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.30

Market Cap

30.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AERT
RNTX
Founded
2012
2001
Country
Singapore
United States
Employees
N/A
11
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.3M
30.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AERT
RNTX
Price
$0.30
$1.30
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
1.1M
94.8K
Earning Date
02-09-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$1.02
52 Week High
$1.52
$2.22

Technical Indicators

Market Signals
Indicator
AERT
RNTX
Relative Strength Index (RSI) 42.65 54.09
Support Level $0.27 $1.06
Resistance Level $0.51 $1.30
Average True Range (ATR) 0.05 0.12
MACD 0.00 -0.00
Stochastic Oscillator 19.84 51.43

Price Performance

Historical Comparison
AERT
RNTX

About AERT Aeries Technology Inc.

Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: